Form 4: United Therapeutics Director Exercises Options and Sells Shares

Christopher Causey, a director at United Therapeutics, exercised stock options and sold 2,000 shares of common stock on June 13, 2024.

Summary

• On June 13, 2024, Christopher Causey, a director of United Therapeutics Corporation, exercised stock options to acquire 2,000 shares of common stock at a price of $112.14 per share.
• Simultaneously, Causey sold 2,000 shares of common stock at a weighted average price of $281.5274, with individual trades ranging from $281.47 to $281.87.
• Following these transactions, Causey directly owns 4,185 shares of United Therapeutics common stock and holds options for 3,000 shares.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the buying and selling activities of company directors. It's common for executives to exercise stock options and sell shares for personal financial management.

Stakeholder Impact

• Shareholders may interpret insider selling as a lack of confidence, but it's also a normal part of executive compensation and portfolio management.

Key Dates